Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Breast Neoplasms 87Colorectal Neoplasms 64Neoplasms 53Pancreatic Neoplasms 52Lung Neoplasms 49Neoplasm Metastasis 45Stomach Neoplasms 43Ovarian Neoplasms 42Rectal Neoplasms 41Esophageal Squamous Cell Carcinoma 34Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 30Leukemia, Myeloid, Acute 28Recurrence 24Triple Negative Breast Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Glioblastoma 21Uterine Cervical Neoplasms 20Small Cell Lung Carcinoma 20Nasopharyngeal Carcinoma 20Fallopian Tube Neoplasms 19Lymphoma, Non-Hodgkin 18Lymphoma 18Colonic Neoplasms 17Prostatic Neoplasms 16Leukemia 15Carcinoma, Ovarian Epithelial 15Melanoma 14

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2capmatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Histologic Type × Drug Therapy × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡